Arcutis Biotherapeutics, Inc. ARQT reported its first-quarter financial results after the bell Tuesday. Here's a look at the highlights.
The Details: Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents.
Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of $14.68 million by 237.66% and represented 1,680% increase over sales of $2.78 million from the same period last year.
The company reported first-quarter net product revenues for its ZORYVE franchise of $21.6 million, with $15 million for ZORYVE (roflumilast) cream 0.3%, and $6.5 million for ZORYVE (roflumilast) topical foam, 0.3%.
“Our strong performance in the first quarter, with the incredibly well-received launch of ZORYVE foam for seborrheic dermatitis, and continued growth of ZORYVE cream in psoriasis, reinforces the demand for new and novel steroid-free treatment options and physician adoption of the ZORYVE portfolio,” said Frank Watanabe, CEO of Arcutis.
“The growth of ZORYVE cream and foam, along with a July 7th PDUFA date for ZORYVE cream as a potential treatment for atopic dermatitis, as well as our robust development pipeline, position Arcutis for a potentially transformative year in 2024.”
ARQT Price Action: According to Benzinga Pro, Arcutis Biotherapeutics shares are up 15.01% at $9.35 after-hours at the time of publication Tuesday.
Related News: What’s Going On With Nikola’s Stock?
Photo: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.